Johnston PB et al. Everolimus plus RCHOP-21 is safe and highly effective for new untreated diffuse large B-cell lymphoma (DLBCL): Results of the phase I trial NCCTG1085 (Alliance). Proc ASH 2015;Abstract 813.

Rule S et al. Ibrutinib vs temsirolimus: Results from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma (MCL). Proc ASH 2015;Abstract 469.

Dreyling M et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, phase 3 study. Lancet 2016;387(10020):770-8. Abstract

Fujiwara H et al. Multicenter phase II study of lenalidomide in patients with relapsed adult T-cell leukemia-lymphoma. Proc ASH 2015;Abstract 181.

Yasenchak CA et al. Brentuximab vedotin with RCHOP as frontline therapy in patients with high-intermediate/high-risk diffuse large B cell lymphoma (DLBCL): Results from an ongoing Phase 2 study. Proc ASH 2015;Abstract 814.

Dr Fanale is Associate Professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center in Houston, Texas.